Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer – Updated Efficacy Data per Claudin 18.2 Expression Level from Study TranStar102/TST001-1002-Cohort C

Transcenta Holding Limited ("Transcenta") presented the progression-free survival (PFS) data from a Phase I/II study of Osemitamab (TST001) plus Capecitabine and Oxaliplatin (CAPOX) as the first-line treatment for advanced gastric/gastroesophageal junction (G/GEJ) cancer. The study showed that the addition of Osemitamab to chemotherapy provided benefit to patients with CLDN18.2 positive tumors, ..